Applications published 14 November 2007

Trofosamide-containing film-coated tablets and method for the production thereof
Baxter International; Baxter Healthcare 1853218*

Production process for NSAID-containing lozenges, their compsns, their medicinal use
Reckitt Benckiser Healthcare 1853219*

Devices for delivering agents to a vaginal tract
Duramed Pharmaceuticals 1853221*

Local treatment of neurofibromas
Nexgenix Pharmaceuticals 1853223*

Thickened spreadable warming lubricant
Ansell Healthcare Products 1853224*

Solid dispersion of hydrophobic bioactive
Pharmaterials 1853225*

Spheroids prepared from an isolated active principle of vegetable origin containing the active prociple or a precursor thereof
Iderne, Michel 1853226*

Pharmaceutical compsn
The Secretary of State for Defence, DSTL Porton Down 1853227*

• Process for the manufacture of microspheres or microcapsules
Sun Pharmaceutical Industries 1853228*

• Compsn for adjusting water quality for administration of water sanitiser sensitive medicaments or vaccines
Salmix Industria e Commerco LTDA 1853229*

• Dosage form and method for sustained release of a substituted pyrazine compound
Jazz Pharmaceuticals 1853230*

• Apparatus and method for transdermal delivery of erythropoietin-based agents
Alza Corp 1853231*

• Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them
Solvay Pharmaceuticals 1853232*

• Preparation with antimicrobial action for external use
Cichos, Christoph; Guggenbichler, J Peter; Cichos, Irmgard 1853233*

• Aerosol and injectable formulations of nanoparticulate benzodiazepine
Elan Pharma International 1853234*

• Methods for improving drug disposition
Novartis 1853235*

• Tablets comprising a biologically active substance and an excipient containing calcium carbonate
Solvay 1853236*

• Substances, compsns and methods for treating alopecia
Relivia 1853237*

• Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
Kosan Biosciences 1853238*

• Use of zeaxanthin for the treatment of diseases of the peripheral retina
DSM 1853239*

• Compsns, methods of use and preparation of 2,6-diisopropyl phenol and analogues for ischaemic injury
Abraxis BioScience 1853240*

• Use of 2-(2-nitro-4-trifluoro-methylbenzoyl)-1,3-cyclohexane-dione in the treatment of Parkinson's disease
Syngenta 1853241*

• Small molecule inhibitors of STAT3 and the uses thereof
The Regents of the University of Michigan 1853242*

• Treatment of hyperproliferative disorders with anthraquinones
Novacea 1853243*

• Method for the treatment of retinopathy or prematurity and related retinopathic diseases
The Scripps Research Institute 1853244*

• Formulations of suberoylanilide hydroxamic acid and methods for producing same
Merck & Co 1853245*

• L-aspartic acid for the treatment of problems in connection with the fat or glucose metabolism
Insituto de Metabolismo Celular 1853246*

• Soap scent patch and treatment for muscle spasm and pain
Ough, Yon Doo 1853247*

• Salts, addition compounds and complex compounds of guanidinoacetic acid
Alzchem Trostberg 1853248*

• A stable pharmaceutical compsn comprising a fixed dose combination of fenofibrate and an HMG-CoA reductase inhibitor
LifeCycle Pharma 1853249*

• Combinations and modes of administration of therapeutic agents and combination therapy
Abraxis BioScience 1853250*

• Boron-containing small molecules
Anacor Pharmaceuticals 1853251*

• Compsns containing polysaccharides
DSM IP Assets 1853252*

• Diosmetin derivatives for the treatment and prevention of thrombotic pathologies
Les Laboratoires Servier 1853253*

• Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
BTG International 1853254*

• Methods for treating arthritis using triheterocyclic compounds
Gemin X Biotechnologies 1853255*

• Organic compounds
Novartis; Novartis-Pharma 1853256*

• Pyrazole compounds
Vivoquest 1853257*

• Medicaments
SmithKline Beecham 1853258*

• Formulation for ocular treatment
Macusight 1853259*

• Substituted pyrazoles as modulators of chemokine receptors
Merck & Co 1853260*

• Selective inhibitors of human corticosteroid synthases
Universitaet des Saarlandes 1853261*

• Pharmaceutical compsn comprising amorphous rosiglitazone
SmithKline Beecham 1853262*

• Compsns and methods for treating dyslipidaemia
Eli Lilly 1853263*

• Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
Sanofi-Aventis 1853264*

• Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
The Government of the United States of America as represented by the Secretary of the Department of Health and Human Sciences; The Progeria Research Foundation; The Regents of the University of Michigan; The University of North Carolina at Chapel Hill 1853265*

• Methods and compsns for treating diabetes, metabolic syndrome and other conditions
Cortendo Invest 1853266*

• Folic acid-, vitamin B6- and vitamin B12-containing agents and the use thereof
Phrontier 1853267*

• Use of sodium channel blockers and their analogues of the treatment of nicotine dependency
Wex Pharmaceuticals 1853268*

• Amide derivatives as ion-channel ligands and pharmaceutical compsns and methods of using the same
Renvois 1853269*

• Pharmaceutical compsns comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
Solvay Pharmaceuticals 1853270*

• Methods and compsn for treating peripheral vascular diseases
Sucampo 1853271*

• Compsns of unconjugated estrogens and methods for their use
Duramed Pharmaceuticals; Diliberti, Charles; Mahashabde, Anu 1853272*

• Pharmaceutical compsn for contraception
Bayer Schering Pharma 1853273*

• 2-methylene-19-nor-(20S-24S)-1alpha, 25-D hydroxyvitamine-D2
Wisconsin Alumni Research Foundation 18563274*

• Formulations of pyridoxal-5"-phosphate and methods of preparation
Medicure International 1853275*

• Compounds inhibiting the aggregation of superoxide dismutase-1
The Brigham & Women's Hospital 1853276*

• Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumours
Gentium 1853277*

• Glucosamine materials
Cartilix 1853278*

• Amide derivatives of hyaluronic acid in osteoarthritis
Fidia Farmaceutica 1853279*

• Compsns and methods for treating and preventing cardiomyopathy and heart disease
The Regents of the University of California 1853280*

• Analgesic and anti-inflammatory compsn
Cambridge Scientific Pty 1853281*

• Method and compsn for repairing epithelial and other cells and tissue
Regenetech 1853282*

• Activating extraction of demineralised bone matrix
The Regents of the University of California; Department of Veterans Affairs 1853283*

• Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic
Technologie Biolactis 1853284*

• Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
Ramot at Tel Aviv University 1853285*

• Compsn for treatment of skin disorders
BMZ Diagnosis 1853286*

• Synthetic peptide copolymers for treatment and prevention of cardiovascular disorders
Yeda Research and Development Co 1853287*

• Intranasal administration of active agents to the central nervous system
Alza Corp 1853288*

• Novel polypeptide ligands for toll-like receptor 2 (TLR2)
Vaxinnate 1853289*

• Anti-hypertensive dietary supplement derived from salmo or oncorhynchus protein hydrolysates
Ocean Nutrition Canada 1853290*

• Bacteriophage and prophage proteins in cancer gene therapy
Austrianova Biotechnology 1853291*

• Pharmaceutical compsn for the prevention and treatment of cancer
Gernot, Truesch 1853292*

• Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
Regenrx Biopharmaceuticals 1853293*

• Anti-angiogenic compounds
Covx Technologies Ireland 1853294*

• Methods and compsns for the treatment of gastrointestinal disorders
Microbia 1853295*

• Use of a cyclic undecapeptide for the preparation of a medicament for administration during myocardial ischaemic events
Debiopharm 1853296*

• Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumour growth in mammalian cells
National Research Council of Canada 1853297*

• Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
Regeneron Pharmaceuticals 1853298*

• Compsns and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
The Regents of the University of California 1853299*

• Methods of using death receptor agonists and EGFR inhibitors
Genentech 1853300*

• Method and compsn for repairing heart tissue
Regenentech 1853301*

• Antiangiogenic agents with aldesleukin
Novartis Vaccines and Diagnostics 1853302*

• Stabilised compsns for topical administration and methods of making the same
DPM Therapeutics 1853303*

• Modulation of MUC1 activity
Dana-Farber Cancer Institute 1853304*

• Survivin peptide vaccine
Survac 1853305*

• Polypeptides from staphylococcus aureus and methods of use
Epitopix 1853306*

• Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralising antibodies
The Government of the United States of America, as represented by The Secretary, The Department of Health and Human Services; The Johns Hopkins University 1853307*

• Bispecific binding agents for modulating biological activity
Merrimack Pharmaceuticals 1853309*

• Anti A beta antibody formulation
Elan Pharma International; Wyeth 1853310*

• Use of parasitic biological agents for prevention and control of allergic and other IGE-mediated disorders
Milestone Research 1853311*

• Methods and compsns for modulating tweak and FN14 activity
Genentech 1853312*

• Particles
Boston Scientific 1853314*

• Treatment for mucositis
Heptagen 1853315*

• Use of an antagonist of EPAC for treating human cardiac hypertrophy
Inserm (Institut National de la Sante et de la Recherche Medicale) 1853316*

• Compsns and methods for treating or preventing flaviviridae infections
Migenix 1853317*

• Layered nanoparticles
Australian Nuclear Science and Technology Organisation 1853318*

• Use of aromatic flavouring agents with high melting point as solubilising agents
Suzuki, Henry Jun 1853319*

• Protein-binding anthracyclin peptide derivatives and medicaments comprising the same
KTB Tumorforschungsgesellschaft 1853320*

• Insulinotropic agents conjugated with structurally well defined branched polymers
Novo Nordisk 1853321*

• Process for preparing maytansinoid antibody conjugates
Immunogen 1853322*